Circulating adiponectin and cardiovascular mortality in patients with type 2 diabetes mellitus: evidence of sexual dimorphism

Table 2 Risk of cardiovascular mortality by 1 SD of circulating adiponectin levels

		Model 1		Model 2
Study samples	Number of participants/events	HR (95% CI)	p value	HR (95% CI)	p value
Men
GHS	242/42	1.41 (1.16-1.70)	5×10⁴	1.54 (1.19-2.01)	1×10³
HPFS	833/146	1.26 (1.10-1.45)	1×10³	1.44 (1.21-1.72)	1×10⁴
POOLED§	1075/188	1.31 (1.17-1.47)	2×10 ⁶	1.47 (1.27-1.70)*	2×10 ⁷
Women
GHS	117/16	1.02 (0.63-1.62)	0.82	0.98 (0.48-2.01)	0.96
NHS	902/144	0.91 (0.75-1.09)	0.31	1.08 (0.86-1.35)	0.49
POOLED ^§	1019/160	0.92 (0.78-1.10)	0.37	1.07 (0.86-1.33)	0.53

GHS, Gargano Heart Study; HPFS, Health Professional Follow-up Study; NHS, Nurses’ Health Study.
Model 1: unadjusted.
Model 2: adjusted for age, sex, smoking habit, BMI, HbA1c, anti-diabetic therapy, hypertension, total cholesterol, HDL cholesterol, triglycerides and hsCRP.
^§pooled analyses were adjusted for “study sample”.
*p = 0.018 vs. model 2, pooled HR in women.

ISSN: 1475-2840